Ministry of Health, Welfare and Sport

Directorate-General for Public Health

Address for visitors:
Parnassusplein 5
2511 VX Den Haag
T 070 340 79 11
F 070 340 78 34

www.rijksoverheid.nl

Information
(10)(2e)
Vaccine development COVID-19
(10)(2e)@minvws.nl

Date
27 May 2020

Aantal pagina's
2

memo

Follow-Up Impfstoffe 28-05-2020

Introduction
Following our consultation on May 26, we hereby send you, as agreed, our first response (10)(2a) This document could also be used as a basis for a broader discussion about the aspects we consider important in a contract. In addition, we will forward information from Johnson&Johnson separately.

We will start this memorandum with a number of topics on which we would like to make further agreements, so that we can accelerate our cooperation at the necessary speed.

Topics for conversation

1) *Governance*

During our meeting we discussed that our nations will be involved on the basis of an equal partnership. We also agreed to define this collaboration more specifically on paper for our upcoming consultation. We hereby propose a brief adequate governance (please see attached overview) as a basis for this conversation. Among other things, the proposal assumes that each country has a support team. We propose that this team will look at the financial and legal aspects, but can also provide a professional assessment of the clinical data supporting the choice to pursue an agreement.

2) *Due diligence*

Knowing the urgency and the need to be able to make choices quickly, we would like to define how we shape the due diligence process. Depending on the form of financing we use, this can be a more or less in-depth process. The type of auditor's report that is already available also determines the depth. We would like to discuss how we combine the desired tempo with a solid consideration.

3) *Review of clinical data*

Our National Institute for Public Health and the Environment (RIVM) has made an indication of promising vaccine developments based on available data. The companies we discussed earlier this week are part of the leading group in that analysis. At the same time, we would like to validate the most recent clinical data when entering into an agreement. How can we design this efficiently? In any case,

we will of course ensure that the necessary scientific knowledge is available in the Netherlands.

4) Legal

We have already confirmed that agreements must of course be legally correct for all four countries. We can also consider broader legal issues when discussing the contract of AstraZeneca. A matter for consideration is to use Belgian law (like other EU-contracts) under Brussels jurisdiction.



Directorate-General for Public Health

Date
27 May 2020